Immunopathogenesis of thyroid eye disease: Emerging paradigms

Survey of Ophthalmology

Volumn 55, Issue 3, 2010, Pages 215-226

  Naik, Vibhavari M ^a,b,d   Naik, Milind N ^a,d,e   Goldberg, Robert A ^a,d   Smith, Terry J ^a,b,d   Douglas, Raymond S ^a,b,c,d  

^a JULES STEIN EYE INSTITUTE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e L V PRASAD EYE INSTITUTE   (India)

Author keywords

Graves ophthalmopathy; Immunology; Orbit; Thyroid eye disease

Indexed keywords

ABATACEPT; ABETIMUS; BELIMUMAB; CD3 ANTIBODY; CD40 ANTIGEN; CORTICOSTEROID; CP 751871; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DT 2219; EPRATUZUMAB; ETANERCEPT; GAMMA INTERFERON; IMC A 12; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; RANTES; RITUXIMAB; SOMATOMEDIN C RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DIPHOSPHATE GLUCOSE DEHYDROGENASE;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL TRIAL; COUGHING; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; HUMAN; HYPERTHERMIA; HYPERTHYROIDISM; HYPOTENSION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION; INFLAMMATION; LUNG NON SMALL CELL CANCER; NEOPLASM; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

AUTOANTIGENS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; ORBIT; RECEPTOR, IGF TYPE 1; T-LYMPHOCYTES;

EID: 77951454787     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2009.06.009     Document Type: Review

References (136)

1. Adams M., Montague C.T., Prins J.B., et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997, 100(12):3149-3153.
2. Agretti P., De Marco G., De Servi M., et al. Evidence for protein and mRNA TSHr expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation. Eur J Endocrinol 2005, 152(5):777-784.
3. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6(3):205-217.
4. Aniszewski J.P., Valyasevi R.W., Bahn R.S. Relationship between disease duration and predominant orbital T-cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000, 85(2):776-780.
5. Avery D.T., Kalled S.L., Ellyard J.I., et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B-cells. J Clin Invest 2003, 112(2):286-297.
6. Bacchetta R., Gregori S., Roncarolo M.G. CD4+ regulatory T-cells: mechanisms of induction and effector function. Autoimmunity Rev 2005, 4(8):491-496.
7. Bahn R.S., Heufelder A.E. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993, 329(20):1468-1475.
8. Bahn R.S. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 2004, 27(3):216-220.
9. Bartalena L., Marcocci C., Pinchera A. Graves' ophthalmopathy: a preventable disease?. Eur J Endocrinol 2002, 146(4):457-461.
10. Bartley G.B., Fatourechi V., Kadrmas E.F., et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996, 121(4):284-290.
11. Bartley G.B., Fatourechi V., Kadrmas E.F., et al. Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996, 121(4):426-434.
12. Bartley G.B. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994, 92:477-588.
13. Bluestone J.A., Tang Q. How do CD4 + CD25+ regulatory T-cells control autoimmunity?. Curr Opin Immunol 2005, 17(6):638-642.
14. Bluestone J.A. Regulatory T-cell therapy: is it ready for the clinic?. Nat Rev Immunol 2005, 5(4):343-349.
15. Bonara P., Vannucchi G., Campi I., et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clin Rev Allergy Immunol 2008, 34(1):118-123.
16. Bour-Jordan H., Salomon B.L., Thompson H.L., et al. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T-cells. J Clin Invest 2004, 114(7):979-987.
17. Boye J., Elter T., Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody Rituximab. Ann Oncol 2003, 14(4):520-535.
18. Braley-Mullen H., Yu S. Early requirement for B-cells for development of spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J Immunol 2000, 165(12):7262-7269.
19. Brix T.H., Petersen H.C., Iachine I., et al. Preliminary evidence of genetic anticipation in Graves' disease. Thyroid 2003, 13:447-451.
20. Brunkow JE., Hjerrild K.A., Paeper B., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27(1):68-73.
21. Burch H.B., Lahiri S., Bahn R.S., et al. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res 1997, 65(2):311-316.
22. Calabrese L.H., Molloy E.S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008, 67:64-65.
23. Cao H.J., Smith T.J. Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. Am J Physiol 1999, 277:1075-1085.
24. Cao H.J., Wang H.S., Zhang Y., et al. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem 1998, 273(45):29615-29625.
25. Carlsen H.S., Baekkevold E.S., Morton H.C., et al. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 2004, 104(10):3021-3027.
26. Cawood T.J., Moriarty P., O'Farrelly C., et al. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 2007, 92(1):59-64.
27. Chen B., Tsui S., Boeglin W.E., et al. Interleukin-4 induces 15-Lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease: evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem 2006, 281(27):18296-18306.
28. Coles A.J., Wing M., Smith S., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. The Lancet 1999, 354(9191):1691-1695.
29. Cooper N., Stasi R., Cunningham-Rundles S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004, 125(2):232-239.
30. Dorkhan M., Lantz M., Frid A., et al. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin Endocrinol (Oxf) 2006, 65(1):35-39.
31. Douglas R.S., Gianoukakis A.G., Kamat S., et al. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 2007, 178(5):3281-3287.
32. Douglas R.S., Naik V., Hwang C.J., et al. B-cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008, 181(8):5768-5774.
33. Drayton D.L., Liao S., Mounzer R.H., Ruddle N.H. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006, 7(4):344-353.
34. Durie F.H., Foy T.M., Noelle R.J. The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease. Res Immunol 1994, 145(3):200-205.
35. Durrani O.M., Reuser T.Q., Murray P.I. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005, 24(2):117-119.
36. Earle K.E., Tang Q., Zhou X., et al. In vitro expanded human CD4 + CD25+ regulatory T-cells suppress effector T-cell proliferation. Clin Immunol 2005, 115(1):3-9.
37. Eckstein A.K., Plicht M., Lax H., et al. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 2004, 61(5):612-618.
38. Edwards J.C.W., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with Rituximab in patients with Rheumatoid Arthritis. N Engl J Med 2004, 350(25):2572-2581.
39. El Fassi D., Nielsen C.H., Hasselbalch H.C., et al. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006, 154(5):623-632.
40. El Yafi F., Winkler R., Delvenne P., et al. Altered expression of type I insulin-like growth factor receptor in Crohn's disease. Clin Exp Immunol 2005, 139(3):526-533.
41. Fassi D.E., Nielsen C.H., Hasselbalch H.C., et al. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006, 16(7):709-710.
42. Feliciello A., Porcellini A., Ciullo I., et al. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 1993, 342(8867):337-338.
43. Fillatreau S., Sweenie C.H., McGeachy M.J., et al. B-cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3(10):944-950.
44. Forster G., Otto E., Hansen C., et al. Analysis of orbital T-cells in thyroid-associated ophthalmopathy. Clin Exp Immunol 1998, 112(3):427-434.
45. Garrity J.A., Bahn R.S. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006, 142(1):147-153.
46. Gerding M.N., van der Meer J.W., Broenink M., et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000, 52(3):267-271.
47. Gianoukakis A.G., Khadavi N., Smith T.J. Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid 2008, 18:953-958.
48. Han R., Smith T.J. Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. J Immunol 2005, 174(5):3072-3079.
49. Han R., Smith T.J. T Helper type 1 and type 2 cytokines exert divergent Influence on the induction of prostaglandin E2 and hyaluronan synthesis by Interleukin-1{beta} in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology 2006, 147(1):13-19.
50. Han R., Tsui S., Smith T.J. Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem 2002, 277(19):16355-16364.
51. Han S., Zhang S., Zhang W., et al. CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: Association study and meta-analysis. Hum Immunol 2006, 67(8):618-626.
52. Harrison N.K., Myers A.R., Southcott A.M., et al. Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (Lond) 1994, 86(2):141-148.
53. Hartog H., Wesseling J., Boezen H.M., et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007, 43(13):1895-1904.
54. Herold K.C., Hagopian W., Auger J.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346(22):1692-1698.
55. Heufelder A.E., Bahn R.S. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest 1993, 23(1):10-17.
56. Heufelder A.E., Dutton C.M., Sarkar G., et al. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 1993, 3(4):297-300.
57. Hiromatsu Y., Kaku H., Miyake I., et al. Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 2002, 12(3):217-221.
58. Huang X., Zhu J., Yang Y. Protection against autoimmunity in nonlymphopenic hosts by CD4 + CD25+ regulatory T-cells is antigen-specific and requires IL-10 and TGF-beta. J Immunol 2005, 175(7):4283-4291.
59. Hufnagel T.J., Hickey W.F., Cobbs W.H., et al. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology 1984, 91:1411-1419.
60. Jacobson D.M. Acetylcholine receptor antibodies in patients with Graves' ophthalmopathy. J Neuroophthalmol 1995, 15(3):166-170.
61. Jameson J.L., Weetman A.P. Disorders of the thyroid gland. Harrison's Principles of Internal Medicine 2001, 2060-2071. McGraw-Hill, New York. A.S. Fauci, E. Braunwald, D.L. Kasper (Eds.).
62. Kaback L.A., Smith T.J. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by Interleukin-1{beta} in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1999, 84(11):4079-4084.
63. Kahaly G., Forster G., Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid 1998, 8(5):429-432.
64. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 Diabetes. N Engl J Med 2005, 352(25):2598-2608.
65. Kohm A.P., Williams J.S., Bickford A.L., et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4 + T-cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005, 174(8):4525-4534.
66. Komorowski J., Jankiewicz-Wika J., Siejka A., et al. Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin Oczna 2007, 109(10-12):457-460.
67. Koulova L., Clark E.A., Shu G., et al. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4 + T-cells. J Exp Med 1991, 173(3):759-762.
68. Koumas L., Smith T.J., Feldon S., et al. Thy-1 Expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol 2003, 163(4):1291-1300.
69. Krassas G.E., Heufelder A.E. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001, 144(4):311-318.
70. Krassas G.E., Pontikides N., Kaltsas T., et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003, 88(1):132-135.
71. Kung A.W., Yau C.C., Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994, 79(2):542-546.
72. Larsen P.R., Davies T.F., Schlumberger M.J. Thyrotoxicosis. Williams Textbook of Endocrinology 2003, 374-421. W.B. Saunders Co, Philadelphia, PA. P.R. Larsen, H.M. Kronenberg, S. Melmed (Eds.).
73. Lee S., Tsirbas A., Goldberg R.A., et al. Thiazolidinedione induced thyroid associated orbitopathy. BMC Ophthalmol 2007, 7:8.
74. Lee T.C., Gold L.I., Reibman J., et al. Immunohistochemical localization of transforming growth factor-beta and insulin-like growth factor-I in asbestosis in the sheep model. Int Arch Occup Environ Health 1997, 69(3):157-164.
75. Levin F., Kazim M., Smith T.J., et al. Rosiglitazone-induced proptosis. Arch Ophthalmol 2005, 123(1):119-121.
76. Li J., Davis J., Bracht M., et al. Modulation of antigen-specific T-cell response by a non-mitogenic anti-CD3 antibody. Int Immunopharmacol 2006, 6(6):880-891.
77. Liu C., Papewalis C., Domberg J., et al. Chemokines and autoimmune thyroid diseases. Horm Metab Res 2008, 40(6):361-368.
78. Looney R.J., Anolik J.H., Campbell D., et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50(8):2580-2589.
79. Ludgate M., Swillens S., Mercken L., et al. Homology between thyroglobulin and acetylcholinesterase: an explanation for pathogenesis of Graves' ophthalmopathy?. Lancet 1986, 2(8500):219-220.
80. Luther S.A., Bidgol A., Hargreaves D.C., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002, 169(1):424-433.
81. Macht L.M., Corrall R.J., Banga J.P., et al. Control of human thyroid autoantibody production in SCID mice. Clin Exp Immunol 1993, 91(3):390-396.
82. Maloney D.G., Liles T.M., Czerwinski D.K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84(8):2457-2466.
83. Manzo A., Paoletti S., Carulli M., et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005, 35(5):1347-1359.
84. Martins J.R., Furlanetto R.P., Oliveira L.M., et al. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2004, 60(6):726-733.
85. McGinness J.L., Bivens M.-M.C., Greer K.E., Patterson J.W., Saulsbury F.T. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol 2006, 55(1):143-148.
86. McKenzie J.M., Zakarija M., Sato A. Humoral immunity in Graves' disease. Clin Endocrinol Metab 1978, 7(1):31-45.
87. Metcalfe R.A., Weetman A.P. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994, 40(1):67-72.
88. Mizokami T., Salvi M., Wall J.R. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?. J Endocrinol Invest 2004, 27(3):221-229.
89. Mohan C., Shi Y., Laman J.D., et al. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995, 154(3):1470-1480.
90. Naik V., Khadavi N., Naik M.N., et al. Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. Thyroid 2008, 18(9):967-971.
91. Nielsen C.H., Fassi D.E., Hasselbalch H.C., et al. B-cell depletion with rituximab in the treatment of autoimmune diseases-Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther 2007, 7(7):1061-1078.
92. O'Garra A., Vieira P. Regulatory T-cells and mechanisms of immune system control. Nat Med 2004, 10(8):801-805.
93. Pappa A., Jackson P., Stone J., et al. An ultrastructural and systemic analysis of glycosaminoglycans in thyroid-associated ophthalmopathy. Eye 1998, 12(Pt 2):237-244.
94. Paridaens D., van den Bosch W.A., van der Loos T.L., et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005, 19(12):1286-1289.
95. Paz K., Hadari Y.R. Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Comb Chem High Throughput Screen 2008, 11(1):62-69.
96. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6(6):644-653.
97. Pichurin P., Aliesky H., Chen C.R., et al. Thyrotrophin receptor-specific memory T-cell responses require normal B-cells in a murine model of Graves' disease. Clin Exp Immunol 2003, 134(3):396-402.
98. Prabhakar B.S., Bahn R.S., Smith T.J. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003, 24(6):802-835.
99. Pritchard J., Horst N., Cruikshank W., et al. Igs from patients with Graves' disease induce the expression of T-cell chemoattractants in their fibroblasts. J Immunol 2002, 168(2):942-950.
100. Pritchard J., Tsui S., Horst N., et al. Synovial fibroblasts from patients with Rheumatoid Arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against Insulin-like growth factor-1 receptor. J Immunol 2004, 173(5):3564-3569.
101. Pritchard Jane H.R., Horst N., Cruikshank W.W., et al. Immunoglobulin activation of T-cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003, 170(12):6348-6354.
102. Prummel M. Pathogenetic and clinical aspects of endocrine ophthalmopathy. Exp Clin Endocrinol Diabetes 1999, 107(Suppl 3):S75-S78.
103. Prummel M.F., Wiersinga W.M. Smoking and risk of Graves' disease. JAMA 1993, 269(4):479-482.
104. Ramsdell F., Seaman M.S., Clifford K.N., et al. CD40 ligand acts as a costimulatory signal for neonatal thymic gamma delta T-cells. J Immunol 1994, 152(5):2190-2197.
105. Rapoport B., McLachlan S.M. The thyrotropin receptor in Graves' disease. Thyroid 2007, 17(10):911-922.
106. Rothe A., Power B.E., Hudson P.J. Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol 2008, 4(11):605-614.
107. Sachdev D., Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006, 11(1):27-39.
108. Salvi M., Vannucchi G., Campi I., et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006, 154(4):511-517.
109. Sempowski G.D., Rozenblit J., Smith T.J., et al. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol 1998, 274(3 Pt 1):C707-C714.
110. Sfikakis P.P., Boletis J.N., Lionaki S., et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52(2):501-513.
111. Shevach E.M. CD4 + CD25 + Suppressor T-cells: more questions than answers. Nat Rev Immunol 2002, 2(6):389-400.
112. Shine B., Fells P., Edwards O.M., et al. Association between Graves' ophthalmopathy and smoking. Lancet 1990, 335(8700):1261-1263.
113. Shishido M., Kuroda K., Tsukifuji R., et al. A case of pretibial myxedema associated with Graves' disease: an immunohistochemical study of serum-derived hyaluronan-associated protein. J Dermatol 1995, 22(12):948-952.
114. Sisson J.C., Schipper M.J., Nelson C.C., et al. Radioiodine therapy and Graves' ophthalmopathy. J Nucl Med 2008, 49(6):923-930.
115. Smith J.A., Bluestone J.A. T-cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol 1997, 9(5):648-654.
116. Smith J.A., Tang Q., Bluestone J.A. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998, 160(10):4841-4849.
117. Smith J.A., Tso J.Y., Clark M.R., et al. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T-cell receptor signal and induce clonal anergy. J Exp Med 1997, 185(8):1413-1422.
118. Smith R.S., Smith T.J., Blieden T.M., et al. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997, 151(2):317-322.
119. Smith T.J., Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004, 89(10):5076-5080.
120. Smith T.J., Koumas L., Gagnon A., et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002, 87(1):385-392.
121. Smith T.J., Wang H.S., Evans C.H. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol 1995, 268(2 Pt 1):C382-C388.
122. Smith T.J. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 2002, 12(3):197-203.
123. Smith T.J. The putative role of fibroblasts in the pathogenesis of Graves disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity 2003, 36(6-7):409-415.
124. Sorisky A., Pardasani D., Gagnon A., et al. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996, 81(9):3428-3431.
125. Spicer A.P., Kaback L.A., Smith T.J., et al. Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem 1998, 273(39):25117-25124.
126. Starkey K.J., Janezic A., Jones G., et al. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 2003, 30(3):369-380.
127. Takemura S., Braun A., Crowson C., et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167(2):1072-1080.
128. Tallstedt L., Norberg R. Immunohistochemical staining of normal and Graves' extraocular muscle. Invest Ophthalmol Vis Sci 1988, 29(2):175-184.
129. Tsui S., Naik V., Hoa N., et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 2008, 181(6):4397-4405.
130. Tuscano J.M., Harris G.S., Tedder T.F. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun Rev 2003, 2(2):101-108.
131. Valyasevi R.W., Erickson D.Z., Harteneck D.A., et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999, 84(7):2557-2562.
132. Valyasevi R.W., Harteneck D.A., Dutton C.M., et al. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 2002, 87(5):2352-2358.
133. Viglietta V., Bourcier K., Buckle G.J., et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008, 71(12):917-924.
134. Weetman A.P., Cohen S., Gatter K.C., et al. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989, 75(2):222-227.
135. Weetman A.P., Yateman M.E., Ealey P.A., et al. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest 1990, 86(3):723-727.
136. Young D.A., Evans C.H., Smith T.J. Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. Proc Natl Acad Sci USA 1998, 95(15):8904-8909.